OR2G2

Across TCGA pan-cancer cohorts, OR2G2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR2G2 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher OR2G2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2G2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

CESC, LUAD, and SKCM are the cancer types where OR2G2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	24	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	18	view →
SKCM	DFS	Median	II,III,IV	0.868	0.673	.006	14	view →
SCLC	DFS	Median	All	0.260	0.817	.005	6	view →
UCEC	OS	Median	All	1.000	0.653	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OR2G2–CESC (OS)

Open the CESC breakdown →